Global Oral Rehydration Solution (ORS) Market

TABLE OF CONTENT 1.1 INTRODUCTION 15 1.1 MARKET SHARE ANALYSIS, 2025 15 1.2 COMPETITOR DASHBOARD 16 1.3 PUBLIC PLAYERS STOCK SUMMARY 17 1.4 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL 17 1.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 18 1.5.1 product LAUNCH 18 1.5.2 PARTNERSHIP 18 1.5.3 labelling 19 1.5.4 product expansion 19 1.5.5 Acquisition 19 2 COMPANY PROFILES 20 2.1 CIPLA 20 2.1.1 COMPANY OVERVIEW 20 2.1.2 FINANCIAL OVERVIEW 21 2.1.3 Products Offered 22 2.1.4 KEY DEVELOPMENTS 22 2.1.5 SWOT ANALYSIS 23 2.1.6 KEY STRATEGIES 23 2.2 ABBOTT 23 2.2.1 COMPANY OVERVIEW 23 Abbott is a diversified global healthcare company with a rich history and a broad portfolio of products across several key healthcare segments. Company’s four reportable segments are Established Pharmaceuticals, Diagnostics, Nutrition, and Medical Devices. Their primary business involves the discovery, development, manufacture, and sale of a wide range of healthcare products. These products are generally sold directly to retailers, wholesalers, hospitals, healthcare facilities, laboratories, physicians’ offices, and government agencies globally. The Established Pharmaceuticals segment includes international sales of branded generic pharmaceutical products. The Nutrition segment covers worldwide sales of both adult and pediatric nutritional products. The Diagnostic Products segment aggregates sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. This segment includes Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics, and Point of Care Diagnostics. The Medical Devices segment encompasses worldwide sales of products for rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care. For reporting purposes, this segment combines divisions such as Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation, and Diabetes Care. Abbott is a leader in diagnostic tests, instruments, and informatics, providing critical information for various health conditions including heart attacks, blood disorders, and cancers. Its portfolio includes top stents, advanced diagnostic devices, thrombectomy systems, and vessel-closure solutions. The company also excels in Electrophysiology with innovative heart rhythm devices and has a leading Structural Heart treatment range with proven, effective, and durable options. In chronic pain therapy, they offer unique solutions like radiofrequency ablation and spinal cord stimulation. Its diverse product lines cover gastroenterology, women’s health, cardiometabolic conditions, and more. In January 2017, Abbott announced the completion of its acquisition of St. Jude Medical, Inc., positioning the company as a leader in the medical device industry. This acquisition enhances Abbott’s potential for future growth and supports its ongoing strategy to build a strong and diversified portfolio across medical devices, diagnostics, nutrition, and branded generic pharmaceuticals. The company has the strong presence across the globe. They operate in Americas, Europe, Middle East, South Africa and Asia Pacific region 24 2.2.2 FINANCIAL OVERVIEW 25 2.2.3 PRODUCTS OFFERED 26 2.2.4 KEY DEVELOPMENTS 26 2.2.5 SWOT ANALYSIS 27 2.2.6 KEY STRATEGIES 27 2.3 SUN PHARMACEUTICAL INDUSTRIES LTD 27 2.3.1 COMPANY OVERVIEW 27 2.3.2 FINANCIAL OVERVIEW 29 2.3.3 products OFFERED 30 2.3.4 KEY DEVELOPMENTs 30 2.3.5 SWOT ANALYSIS 30 2.3.6 KEY STRATEGIES 31 2.4 DR. REDDY’S LABORATORIES LTD 32 2.4.1 COMPANY OVERVIEW 32 2.4.2 FINANCIAL OVERVIEW 33 2.4.3 PRODUCTS Offered 34 2.4.4 KEY DEVELOPMENTS 34 2.4.5 SWOT ANALYSIS 34 2.4.6 KEY STRATEGIES 35 2.5 UNILEVER 36 2.5.1 COMPANY OVERVIEW 36 Unilever is one of the world’s largest and most influential multinational companies, with a diverse and expansive portfolio across beauty and personal care, home care, food and beverages, and health & wellbeing sectors. The company is particularly strong in the beauty and personal care market, competing globally for leadership in hair care and skin care, with notable success in Asia where its skin care products, including Dove, POND’s, and Vaseline, have built a loyal consumer base. In the high-growth prestige beauty segment, Unilever has established a strong presence in premium skin care, hair care, and color cosmetics, with an expanding portfolio in vitamins, minerals, and supplements. These efforts are aligned with the company's broader focus on health and wellness, offering products that meet the rising demand for healthier lifestyles. Unilever’s skin cleansing business is the largest category in its personal care division, with market-leading brands like Dove dominating globally. The company’s deodorants portfolio is another area of strength, with brands like Rexona (Degree) and Dove utilizing advanced, science-backed technologies to deliver superior protection and performance. In oral care, Unilever’s brands, including Pepsodent and Closeup, focus on core propositions like anti-cavity protection and freshness, maintaining strong positions in key global markets. In home care, Unilever is the second-largest global player, with a commanding position in emerging markets. The company’s portfolio spans fabric cleaning, fabric enhancers, and home hygiene categories, with trusted brands such as Omo, Surf, Cif, and Domestos. These products continue to lead through innovation, offering consumers more effective, environmentally-friendly solutions, including those that reduce water usage and plastic waste. Unilever is also one of the largest players in the foods sector, with iconic brands like Knorr and Hellmann’s, leading in scratch cooking and dressings. Knorr continues to dominate with its range of bouillons, soups, and seasonings, while Hellmann’s remains a leader in the mayonnaise and dressings categories. The company’s strong portfolio and diverse geographic reach allow it to thrive in both emerging and developed markets, ensuring it remains a powerful force in the global FMCG industry 36 2.5.2 FINANCIAL OVERVIEW 37 2.5.3 PRODUCTS OFFERED 38 2.5.4 KEY DEVELOPMENTS 38 2.5.5 SWOT ANALYSIS 39 2.5.6 KEY STRATEGIES 39 2.6 MANKIND PHARMA 40 2.6.1 COMPANY OVERVIEW 40 Mankind Pharma Limited is one of India’s leading pharmaceutical companies, headquartered in New Delhi, known for its strong presence across both prescription pharmaceuticals and consumer healthcare segments. The company has built a highly diversified healthcare portfolio spanning generics, super-specialty therapies, and consumer health products, supported by strong in-house research and development capabilities and a deeply penetrated distribution network across India. Mankind Pharma has established one of the strongest domestic sales and marketing networks in the Indian pharmaceutical industry, enabling wide accessibility of its products across urban and rural markets. The company operates through 32 state-of-the-art manufacturing facilities and 6 dedicated R&D centers, with over 75% of production carried out in-house, ensuring strong quality control, cost efficiency, and supply chain reliability. Its manufacturing ecosystem is further strengthened by local procurement of over 95% of raw materials, reducing dependency on imports and improving operational resilience. With a massive installed production capacity exceeding 44 billion units annually, Mankind Pharma is well-positioned to meet large-scale domestic and international demand. The company also employs a strong technical workforce, including over 5,100 manufacturing personnel and more than 730 scientists, many of whom are highly qualified research professionals, including PhD holders. Mankind Pharma’s pharmaceutical portfolio covers more than 10 major acute and chronic therapeutic areas such as anti-infectives, cardiology, gastrointestinal disorders, diabetes, respiratory diseases, neurology/CNS, dermatology, and vitamins and nutritional supplements. Alongside prescription medicines, the company has a strong consumer healthcare division offering widely recognized brands in categories such as condoms, pregnancy detection kits, antacid powders, vitamin and mineral supplements, oral contraceptives, and anti-acne products. A major strategic milestone in the company’s growth journey was the acquisition of Bharat Serums and Vaccines Limited, which significantly expanded its presence in high-barrier, super-specialty segments such as women’s healthcare, fertility, and critical care 40 2.6.2 FINANCIAL OVERVIEW 41 2.6.3 PRODUCTS OFFERED 42 2.6.4 KEY DEVELOPMENTS 42 2.6.5 KEY STRATEGIES 42 2.7 PRESTIGE CONSUMER HEALTHCARE INC 42 2.7.1 COMPANY OVERVIEW 42 Prestige Consumer Healthcare Inc. is a leading consumer healthcare company that develops, markets, manufactures, and distributes a broad portfolio of over-the-counter (OTC) healthcare and personal care products across the United States, Canada, Australia, and selected international markets. The company has built its business through a combination of organic growth and strategic acquisitions, focusing on well-established brands that hold strong positions in niche healthcare categories. Its portfolio spans key segments such as analgesics, cough and cold remedies, women's health, gastrointestinal care, eye and ear care, dermatological products, and oral care. Prestige's strategy centers on brand building, leveraging targeted marketing investments, product innovation, and line extensions to strengthen brand equity and meet evolving consumer needs. The company benefits from a diversified portfolio and broad distribution network that includes mass merchandisers, drug stores, supermarkets, convenience stores, club stores, dollar stores, and e-commerce platforms. This diversity allows Prestige to maintain resilience during market disruptions and shift marketing focus across categories when challenges arise. Innovation is a key growth driver, supported by a multi-year product development pipeline that introduces new formulations, flavors, ingredients, and health benefits designed to enhance consumer satisfaction and expand category growth. Operationally, the company utilizes a centralized third-party logistics model in the United States, enabling efficient warehousing, transportation, inventory management, and product distribution. Through its strong brand portfolio, consumer-centric innovation, and extensive retail presence, Prestige Consumer Healthcare has established itself as a significant player in the North American and international OTC healthcare market 43 2.7.2 FINANCIAL OVERVIEW 44 2.7.3 PRODUCTS OFFERED 45 2.7.4 KEY DEVELOPMENTS 45 2.7.5 KEY STRATEGIES 45 2.8 OTSUKA HOLDINGS CO., LTD 46 2.8.1 COMPANY OVERVIEW 46 Otsuka Holdings Co., Ltd. is a global healthcare company and a core member of the broader Otsuka Holdings Co., Ltd. group, which operates approximately 200 companies worldwide. The company follows a unique healthcare philosophy that focuses not only on treating diseases but also on supporting overall health, well-being, and disease prevention. Through its integrated business model, Otsuka addresses a wide range of healthcare and societal needs by combining pharmaceutical innovation with nutraceutical and consumer health solutions. Its operations span across more than 32 countries and regions, enabling the company to deliver healthcare products and services on a global scale while responding to region-specific health challenges. Otsuka's business activities are organized into four major segments: pharmaceuticals, nutraceuticals, consumer products, and other supporting businesses. The pharmaceutical segment includes therapeutic drugs, clinical nutrition products, diagnostics, medical devices, bulk pharmaceuticals, and intermediates. The nutraceutical business focuses on functional foods and beverages, cosmedics, over-the-counter (OTC) products, and quasi-drugs that support health maintenance and preventive care. In the consumer products segment, Otsuka offers beverages, foods, and wine, while its other businesses include chemicals, packaging, warehousing and distribution, and electronic equipment. This diversified structure allows the company to create synergies across healthcare, nutrition, and consumer wellness markets. The company operates an extensive global research network and invests heavily in innovative drug discovery and healthcare solutions. Its research strengths include psychiatry and neurology, oncology, clinical nutrition, and medical devices, supported by specialized group companies. By combining pharmaceutical innovation with preventive healthcare products, Otsuka is uniquely positioned to address the growing convergence between healthcare and consumer wellness. The company has also achieved strong international expansion through globally recognized products and therapies, including hydration solutions and treatments for infectious diseases, demonstrating its commitment to improving health outcomes and contributing to societal well-being worldwide 46 2.8.2 FINANCIAL OVERVIEW 47 2.8.3 PRODUCTS OFFERED 48 2.8.4 KEY DEVELOPMENTS 48 2.8.5 KEY STRATEGIES 48 2.9 FDC LIMITED 50 2.9.1 COMPANY OVERVIEW 50 FDC Limited is a people-focused global healthcare organization engaged in the innovation, manufacture, and marketing of high-quality pharmaceutical and wellness products aimed at improving human health and enhancing shareholder value. The company has built a strong reputation in India and international markets by consistently responding to evolving healthcare needs through a diversified portfolio that includes prescription medicines, branded generics, nutraceuticals, functional foods, and over-the-counter (OTC) products. It has a significant presence in therapeutic areas such as anti-infectives, gastrointestinal care, cardiovascular and anti-diabetic therapies, ophthalmology, dermatology, respiratory care, gynecology, analgesics, and pediatric care. A key milestone in its history is its pioneering role in oral rehydration salts (ORS), which continues to be an important part of its preventive healthcare offerings. FDC’s portfolio is supported by a wide range of dosage forms including tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and child-friendly formulations, enabling it to address diverse patient needs across different age groups. The company places strong emphasis on quality, regulatory compliance, and innovation, allowing it to serve both domestic and international markets across more than 50 countries. Its growth strategy is supported by robust R&D capabilities, digitally enabled operations, and an efficient supply chain that enhances manufacturing and distribution efficiency. In addition to its pharmaceutical strengths, FDC has expanded into preventive healthcare through functional foods and nutraceuticals, reflecting the rising global demand for wellness-oriented products. Its offerings include flavored ORS powders, electrolyte beverages, vitamin and mineral supplements, antioxidant blends, and protein-fortified drinks that support hydration, immunity, energy, and nutritional balance. The company also strengthens its formulation business through in-house production of select active pharmaceutical ingredients (APIs), ensuring cost efficiency, supply security, and consistent product quality 50 2.9.2 FINANCIAL OVERVIEW 52 2.9.3 PRODUCTS OFFERED 52 2.9.4 KEY DEVELOPMENTS 53 2.9.5 KEY STRATEGIES 53 2.10 WALLACE PHARMACEUTICALS 53 2.10.1 COMPANY OVERVIEW 53 Wallace Pharmaceuticals is a diversified pharmaceutical organization committed to improving human health through the development, manufacturing, and marketing of high-quality medicines, nutraceuticals, and cosmeceutical products. Founded and owned by the Menzes family, the company carries a strong legacy in the Indian pharmaceutical industry and has contributed significantly to its growth through decades of experience, innovation, and global expansion. It has built a well-established presence across emerging markets in Africa, Asia, and Latin America, while now actively pursuing expansion into regulated markets such as Europe, North America, Australia, and Russia to strengthen its global footprint. The company maintains a broad and diversified product portfolio spanning multiple therapeutic areas, including cardiology, gastroenterology, neurology, respiratory diseases, anti-infectives, orthopedics, and gynecology, along with a strong presence in over-the-counter (OTC), nutraceutical, and dermatology-focused cosmeceutical segments. In addition to its branded formulations business, Wallace Pharmaceuticals also engages in contract manufacturing for reputed international pharmaceutical companies, further enhancing its global business reach and revenue streams. A key driver of its innovation capability is the Wallace Innovation Centre (WIC), a state-of-the-art R&D facility located in Goa, which is approved by the Department of Scientific and Industrial Research (DSIR), India. This center serves as a comprehensive development hub for pharmaceutical, nutraceutical, and cosmetic products, with capabilities in formulation development, analytical testing, scale-up, and commercialization. It supports a wide range of dosage forms including tablets, capsules, dry powder suspensions, pellets, syrups, creams, ointments, gels, and liquids, enabling the company to address diverse patient and consumer needs 54 2.10.2 FINANCIAL OVERVIEW 54 2.10.3 PRODUCTS OFFERED 54 2.10.4 KEY DEVELOPMENTS 56 2.10.5 KEY STRATEGIES 56 3 DATA CITATIONS 57

LIST OF TABLES TABLE 1 PRODUCT LAUNCH 21 TABLE 2 PARTNERSHIP 21 TABLE 3 LABELLING 23 TABLE 4 PRODUCT EXPANSION 23 TABLE 5 ACQUISITION 23 TABLE 6 CIPLA: PRODUCTS OFFERED 26 TABLE 7 CIPLA: KEY DEVELOPMENTS 27 TABLE 8 ABBOTT: PRODUCTS OFFERED 32 TABLE 9 ABBOTT: KEY DEVELOPMENTS 33 TABLE 10 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 37 TABLE 11 DR. REDDY’S LABORATORIES LTD.: PRODUCTS OFFERED 43 TABLE 12 UNILEVER: PRODUCTS OFFERED 47 TABLE 13 UNILEVER: KEY DEVELOPMENTS 47 TABLE 14 MANKIND PHARMA: PRODUCTS OFFERED 53 TABLE 15 PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCTS OFFERED 56 TABLE 16 OTSUKA HOLDINGS CO., LTD.: PRODUCTS OFFERED 59 TABLE 17 OTSUKA HOLDINGS CO., LTD.: KEY DEVELOPMENTS 59 TABLE 18 FDC LIMITED: PRODUCTS OFFERED 63 TABLE 19 WALLACE PHARMACEUTICALS: PRODUCTS OFFERED 66 LIST OF FIGURES FIGURE 1 GLOBAL ORAL REHYDRATION SOLUTION (ORS) MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 17 FIGURE 2 COMPETITOR DASHBOARD: GLOBAL ORAL REHYDRATION SOLUTION (ORS) MARKET 18 FIGURE 3 CIPLA: FINANCIAL OVERVIEW SNAPSHOT 25 FIGURE 4 CIPLA: SWOT ANALYSIS 28 FIGURE 5 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT 31 FIGURE 6 ABBOTT: SWOT ANALYSIS 34 FIGURE 7 SUN PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 36 FIGURE 8 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS 38 FIGURE 9 DR. REDDY’S LABORATORIES LTD.: FINANCIAL OVERVIEW SNAPSHOT 41 FIGURE 10 DR. REDDY’S LABORATORIES LTD.: SWOT ANALYSIS 43 FIGURE 11 UNILEVER: FINANCIAL OVERVIEW SNAPSHOT 46 46 FIGURE 12 UNILEVER: SWOT ANALYSIS 49 FIGURE 13 MANKIND PHARMA: FINANCIAL OVERVIEW SNAPSHOT 52 SOURCE: ANNUAL REPORT, PRESS RELEASES, AND MRFR ANALYSIS 52 FIGURE 14 PRESTIGE CONSUMER HEALTHCARE INC.: FINANCIAL OVERVIEW SNAPSHOT 55 55 FIGURE 15 OTSUKA HOLDINGS CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT 58 SOURCE: ANNUAL REPORT, PRESS RELEASES, AND MRFR ANALYSIS 58 FIGURE 16 FDC LIMITED: FINANCIAL OVERVIEW SNAPSHOT 63 63